Treating women with juvenile myoclonic epilepsy

Practical Neurology

Volumn 9, Issue 5, 2009, Pages 268-277

  Craig, John J ^a   Hunt, Stephen J ^a  

^a ROYAL GROUP OF HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ABSENCE; ARTICLE; CHEMICALLY INDUCED DISORDER; CONGENITAL DISORDER; DRUG EFFECT; FEMALE; HUMAN; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE; WOMEN'S HEALTH;

ANTICONVULSANTS; CONGENITAL ABNORMALITIES; EPILEPSY, ABSENCE; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; WOMEN'S HEALTH;

EID: 77949318543     PISSN: 14747758     EISSN: 14747766     Source Type: Journal    
DOI: 10.1136/jnnp.2009.187898     Document Type: Article

References (45)

1. Schachter SC. Quality of life for patients with epilepsy is determined by more than seizure control: the role of psychosocial factors. Exp Rev Neurother 2006;6:111-18.
2. Marson AG, Al-Kharusi AM, Alwaidh M, et al, SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007;369:1016-26.
3. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a populationbased study in Iceland. Epilepsia 1998;39:887-92.
4. De Swiet M. Other indirect deaths. In: Lewis L, ed. Why mothers die 2000-2002: the Sixth Report of Confidential Enquiries into Maternal Deaths in the UK. London: RCOG Press, 2004.
5. Millward-Sadler H. Pathology. In: Lewis L, ed. Why mothers die 2000-2002: the Sixth Report of Confidential Enquiries into Maternal Deaths in the UK. London: RCOG Press, 2004.
6. Williams J, Myson V, Sterard S, et al. Selfdiscontinuation of antiepileptic medication in pregnancy: detection by hair analysis. Epilepsia 2002;43:824-31.
7. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-83.
8. Teramo K, Hiilesmaa V. Pregnancy and fetal complications in epileptic pregnancies. In: Janz D, Dam M, Richens A, et al, eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982:53-9.
9. The EURAP Study Group. Seizure control and treatment in pregnancy. Observations from the EURAP Epilepsy Pregnancy Registry. Neurology 2006;66:354-60.
10. Samren EB, Van Duijn CM, Christiaens L, et al. Antiepileptic drug regimes and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-46.
11. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anti convulsant drugs. N Engl J Med 2001;344:1132-8.
12. Samren EB, Van Duijin C, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-90.
13. Canger R, Battino D, Canevini MP, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999;40:1231-6.
14. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-8.
15. Kaaja E, Kaaja R, Hiilessmaa V. Major malformations in offspring of women with epilepsy. Neurology 2003;60:575-9.
16. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-8.
17. Meischenguiser R, D'Giano CH, Ferraro SM. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 2004;5:163-7.
18. Robert E, Guiabud P. Maternal valproic acid and congenital neural tube defects. Lancet 1982;2:937.
19. Wyszynski D, Nambisan M, Surve T, et al, for the Antiepileptic Drug Pregnancy Registry. Increased risk of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-5.
20. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure. Fetal death and malformations. Neurology 2006;67:407-12.
21. Vadja FJE, Hitchcock A, Graham J, et al. Foetal malformations and seizure control: 52 months data of the Australian Pregnancy Registry. Eur J Neurol 2006;13:645-54.
22. Duncan S, Mercho S, Lopes-Cended I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001;42:750-3.
23. Faiella A, Wernig M, Consalez GC, et al. A mouse model for valproate teratogenicity: parental effects, homeotic transformations, and altered HOX expression. Hum Mol Genetics 2000;9:227-36.
24. Diliberti JH, Farndon PA, Dennis NR, et al. The fetal valproate syndrome. Am J Med Genet 1984;19:473-81.
25. Kinu U, Adab N, Vinten J, et al. Dysmorphic features: on important clue to the diagnosis and severity of anticonvulsant syndromes, Liverpool and Manchester Neurodevelopmental Study Group. Arch Dis Child Fetal Neonatal Ed 2006;91:F90-5.
26. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21.
27. Eriksson K, Viinikainen K, Monkkonen A, et al. Children exposed to valproate in utero-population based evaluation of risks and confounding factors for long-term neurocognitive development. Epilepsy Res 2005;65:189-200.
28. Adab N, Tudur SC, Vinten J, et al. Common antiepileptic drugs in pregnancy in women with epilepsy (Cochrane review). Cochrane Database Syst Rev 2003;3:CD004848.
29. Thomas SV, Ajaykumar B, Sindhu K, et al. Motor and mental development of infants exposed to antiepileptic drugs in utero. Epilepsy Behav 2008;13:229-36.
30. Thomas SV, Sukumaran S, Lukose N, et al. Intellectual and language functions in children in mothers with epilepsy. Epilepsia 2007;48:2234-40.
31. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3 years after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597-605.
32. Rasalam AD, Hailey H, Williams JH, et al. Characteristics of fetal anticonvulsant syndrome associated autistic disorder. Dev Med Child Neurol 2005;47:551-5.
33. Tennis P, Eldridge RR, International Lamotrigine Pregnancy Registry Scientific Advisory Committee: Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002;43:1161-7.
34. Cunnington M, Ferber S, Quartey G. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007;48:1207-10.
35. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008;70:2152-8.
36. Dolk H, Jentink J, Loane M, et al, on behalf of the EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations? Neurology 2008;71:714-22.
37. Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008;71:272-6.
38. Ornoy A, Zvi N, Arnon J, et al. The outcome of pregnancy following topiramate treatment: A study on 52 pregnancies. Reprod Toxicol 2008;25:388-9.
39. Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006;67:1876-9.
40. Holmes LB, Smith CR, Hernandez-Diaz S. Pregnancy registries: Larger sample sizes essential. Birth Defects Research (part A) 2008;82:307.
41. Bell GS, Nashef L, Kendall, et al. Information recalled by women taking anti-epileptic drugs for epilepsy: a questionnaire study. Epilepsy Res 2002;52:139-46.
42. Crawford P, Appleton R, Betts T, et al. Best practice guidelines for the management of women with epilepsy. The Women with Epilepsy Guidelines Development Group. Seizure 1999;8:210-17.
43. Stokes T, Shaw EJ, Juarez-Garcia A, et al. Clinical guidelines and evidence review for the epilepsies: diagnosis and management in adults and children in primary and secondary care. London: Royal College of General Practitioners, 2004.
44. Hernandez-Diaz S, Werler MM, Walker AM, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-14.
45. Morrow JI, Hunt SJ, Russell AJ, et al. Folic acid use and congenital malformations in offspring of women with epilepsy. A prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2009;80:506-11.